5 Factors That May Affect Multiple Myeloma Outcomes
What are some of the most important factors affecting outcomes in patients with multiple myeloma?
What are some of the most important factors affecting outcomes in patients with multiple myeloma?
Critically ill patients with cancer who develop delirium have a higher risk of dying in the hospital or intensive care unit, a study suggests.
Iomab-B plus RIC enables ASCT in a population of AML patients who are not typically eligible for transplant, a phase 3 study suggests.
Adding ibrutinib to induction and maintenance after transplant improves failure-free survival in patients with mantle cell lymphoma, results of the TRIANGLE study suggest.
Neither a higher dose of daunorubicin nor a second induction cycle improved outcomes in fit patients with newly diagnosed acute myeloid leukemia.
Randomized noninferiority study compared outcomes for patients with neutropenia after HSCT who followed a protective diet with those who followed a nonrestrictive diet.
A real-world study provides a benchmark for survival in MCL patients for whom BTK inhibitor treatment has failed, according to researchers.
Researchers sought to determine whether azacitidine plus venetoclax would be effective in patients with high-risk MDS or chronic myelomonocytic leukemia.
Final results from ICARIA-MM support isatuximab plus pomalidomide and dexamethasone as a standard of care for relapsed/refractory multiple myeloma, according to researchers.
Zanubrutinib can improve progression-free survival, when compared with bendamustine-rituximab, in previously untreated CLL/SLL, a phase 3 trial suggests.